Manuela Gernert

Prof. Manuela Gernert

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Experimental Neurology
Verified
Journal Article
Closed access
MGManuela Gernert
Manuela Gernert
KTKerry W. Thompson
Kerry W. Thompson
WLWolfgang Löschera
Wolfgang Löschera
ATAllan J. Tobin
Allan J. Tobin

15 August 2002 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MGManuela Gernert
Manuela Gernert
MBMustapha Bennay
Mustapha Bennay
MFMaren Fedrowitz
Maren Fedrowitz
JRJan H. Rehders
Jan H. Rehders
ARAngelika Richter
Angelika Richter
A decreased activity of basal ganglia output neurons is thought to underlie idiopathic dystonias and other hyperkinetic movement disorders. We found recently a reduced spontaneous discharge rate of entopeduncular neurons (internal globus pallidus in primates) indtsz hamsters, an unique model for idiopathic paroxysmal dystonia in which stress-inducible attacks show an age-dependent severity. Otherwise, it has been suggested that an altered discharge pattern may be more important for the occurrence of dystonia than a reduced discharge rate. Based on qualitative and computerized quantitative evaluations of interspike interval histograms and spike trains of extracellularly recorded single neurons, we investigated the spontaneous discharge pattern of GABAergic entopeduncular and nigral neurons indtsz hamsters at different ages. The discharge pattern of entopeduncular neurons was highly irregular and showed an altered burst-like firing indtsz hamsters at the age of the most marked expression of dystonia when compared with age-matched nondystonic controls. In line with a recently reported normalization of discharge rates after age-dependent disappearance of dystonia, we found an almost complete normalization of the discharge pattern of entopeduncular neurons after remission of dystonia indtsz hamsters. Investigations of GABAergic nigral neurons, reported recently to have the same spontaneous discharge rates in dystonic and nondystonic hamsters, did not show an altered firing pattern indtsz hamsters. The present data clearly indicate the fundamental importance of an altered discharge pattern of entopeduncular neurons for the expression of paroxysmal dystonia, and probably also for other dyskinesias, and may explain the improvements obtained by pallidotomy in dystonic patients despite an obviously reduced pallidal output.

24 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGManuela Gernert
Manuela Gernert
MFMalte Feja
Malte Feja
Epilepsies are common chronic neurological diseases characterized by recurrent unprovoked seizures of central origin. The mainstay of treatment involves symptomatic suppression of seizures with systemically applied antiseizure drugs (ASDs). Systemic pharmacotherapies for epilepsies are facing two main challenges. First, adverse effects from (often life-long) systemic drug treatment are common, and second, about one-third of patients with epilepsy have seizures refractory to systemic pharmacotherapy. Especially the drug resistance in epilepsies remains an unmet clinical need despite the recent introduction of new ASDs. Apart from other hypotheses, epilepsy-induced alterations of the blood–brain barrier (BBB) are thought to prevent ASDs from entering the brain parenchyma in necessary amounts, thereby being involved in causing drug-resistant epilepsy. Although an invasive procedure, bypassing the BBB by targeted intracranial drug delivery is an attractive approach to circumvent BBB-associated drug resistance mechanisms and to lower the risk of systemic and neurologic adverse effects. Additionally, it offers the possibility of reaching higher local drug concentrations in appropriate target regions while minimizing them in other brain or peripheral areas, as well as using otherwise toxic drugs not suitable for systemic administration. In our review, we give an overview of experimental and clinical studies conducted on direct intracranial drug delivery in epilepsies. We also discuss challenges associated with intracranial pharmacotherapy for epilepsies.

9 November 2011 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KTKathrin Töllner
Kathrin Töllner
SWSaskia Wolf
Saskia Wolf
WLWolfgang Löscher
Wolfgang Löscher
MGManuela Gernert
Manuela Gernert
Resistance to antiepileptic drugs (AEDs) is a major problem in epilepsy treatment. However, mechanisms of resistance are only incompletely understood. We have recently shown that repeated administration of the AED phenytoin allows selecting resistant and responsive rats from the amygdala kindling model of epilepsy, providing a tool to study mechanisms of AED resistance. We now tested whether individual amygdala-kindled rats also differ in their anticonvulsant response to the major AED valproate (VPA) and which mechanism may underlie the different response to VPA. VPA has been proposed to act, at least in part, by reducing spontaneous activity in the substantia nigra pars reticulata (SNr), a main basal ganglia output structure involved in seizure propagation, seizure control, and epilepsy-induced neuroplasticity. Thus, we evaluated whether poor anticonvulsant response to VPA is correlated with low efficacy of VPA on SNr firing rate and pattern in kindled rats. We found (1) that good and poor VPA responders can be selected in kindled rats by repeatedly determining the effect of VPA on the electrographic seizure threshold, and (2) a significant correlation between the anticonvulsant response to VPA in kindled rats and its effect on SNr firing rate and pattern. The less VPA was able to raise seizure threshold, the lower was the VPA-induced reduction of SNr firing rate and the VPA-induced regularity of SNr firing. The data demonstrate for the first time an involvement of the SNr in pharmacoresistant experimental epilepsy and emphasize the relevance of the basal ganglia as target structures for new treatment options.

4 October 2004 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MGManuela Gernert
Manuela Gernert
MFMaren Fedrowitz
Maren Fedrowitz
PWPiotr Wlaź
Piotr Wlaź
WLWolfgang Löscher
Wolfgang Löscher

1 September 2008 in Neurobiology of Disease
Verified
Journal Article
Closed access
MNMarc W. Nolte
Marc W. Nolte
WLWolfgang Löscher
Wolfgang Löscher
CHChristiane Herden
Christiane Herden
WFWilliam J. Freed
William J. Freed
MGManuela Gernert
Manuela Gernert